White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
One Percent Rule Checklist For Safer Forex Trading Risk 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
BRISBANE, Calif., April 21, 2017 -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients, announces the appointment of Michael Bell as Chief Financial Officer joining CareDx effective April 21, 2017, and succeeding Charles Constanti. The board and the company thank Mr. Constanti for his valuable contributions and financial expertise during their acquisition year. Mr. Constanti will remain with the company until June 30th to facilitate a smooth transition.
"CareDx is gearing up for the launch of AlloSure, its next-generation post-transplant rejection testing service, while at the same time driving its existing transplantation product lines, AlloMap and Olerup, towards profitability," said Peter Maag, CareDx president and chief executive officer. "Michael’s broad experience in finance and operations, coupled with his knowledge of the diagnostics industry, will guide our efforts to provide novel diagnostic solutions to transplantation physicians and patients, while delivering value to our shareholders."
Michael Bell brings over 20 years of international finance and accounting experience. Michael is the former CFO of Metabiota, an infectious disease risk analytics company. Previously, he served as the CFO of Singulex, a clinical diagnostics company, and has held leadership and executive positions within Novartis, including tenure as the CFO of Novartis Diagnostics, a global provider of blood screening solutions. Previously, Michael worked in public accounting at Ernst & Young and Deloitte. Michael holds a Bachelor of Science degree in Mathematics with Computing from the University of Leicester in the United Kingdom, and is a Fellow of the Institute of Chartered Accountants in England & Wales.
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. CareDx offers AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate to severe acute cellular rejection. CareDx is developing additional products for transplant monitoring using a variety of technologies, including AlloSure®, a proprietary next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation.
CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP® is a set of HLA typing used prior to hematopoietic stem cell/bone marrow transplantation and organ transplantation. XM-ONE® is the first standardized test that quickly identifies a patient’s antigens against HLA Class I, Class II or antibodies against a donor’s endothelium.
For more information, please visit: www.CareDx.com.
Contact Sasha King, Head of Marketing T: +1 415-287-2393 E: [email protected]
